Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
暂无分享,去创建一个
R Sinkus | J. Waterton | R. Sinkus | S. Robinson | Y. Jamin | J. Boult | J. Bamber | S P Robinson | J C Waterton | J C Bamber | J Li | Y Jamin | J K R Boult | C Cummings | J Ulloa | C. Cummings | J. Ulloa | J. Li
[1] Septimiu E. Salcudean,et al. Transperineal prostate MR elastography: Initial in vivo results , 2013, Magnetic resonance in medicine.
[2] Chryso Kanthou,et al. Disrupting tumour blood vessels , 2005, Nature Reviews Cancer.
[3] John C Waterton,et al. Qualification of imaging biomarkers for oncology drug development. , 2012, European journal of cancer.
[4] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[5] F. Schaefer,et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography. Part 1: Basic Principles and Technology , 2013, Ultraschall in der Medizin.
[6] V. Vilgrain,et al. MR elastography of liver tumours: value of viscoelastic properties for tumour characterisation , 2012, European Radiology.
[7] J. Waterton,et al. Translational Magnetic Resonance Imaging and Spectroscopy: Opportunities and Challenges , 2013 .
[8] F. Westwood,et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] S. Walker-Samuel,et al. The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function , 2012, British Journal of Cancer.
[10] P. Choyke,et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.
[11] R. Sinkus,et al. High-resolution tensor MR elastography for breast tumour detection. , 2000, Physics in medicine and biology.
[12] Mickael Tanter,et al. MR elastography of breast lesions: Understanding the solid/liquid duality can improve the specificity of contrast‐enhanced MR mammography , 2007, Magnetic resonance in medicine.
[13] D. Blakey,et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. , 2002, Cancer research.
[14] H. Dvorak,et al. Tumor microenvironment and progression , 2011, Journal of surgical oncology.
[15] M. Horsman,et al. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. , 2006, Cancer research.
[16] J. Waterton. CHAPTER 12:Translational Magnetic Resonance Imaging and Spectroscopy: Opportunities and Challenges , 2013 .
[17] Ralph Sinkus,et al. Colon tumor growth and antivascular treatment in mice: complementary assessment with MR elastography and diffusion-weighted MR imaging. , 2012, Radiology.
[18] J. Waterton,et al. False-negative MRI biomarkers of tumour response to targeted cancer therapeutics , 2012, British Journal of Cancer.
[19] J. Griffiths,et al. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. , 2006, Microvascular research.
[20] R Sinkus,et al. MR elastography of the breast:preliminary clinical results. , 2002, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.
[21] Martin O. Leach,et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial , 2009, European Radiology.
[22] A. Balmain,et al. Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.
[23] D. Yeung,et al. MR elastography of the head and neck: driver design and initial results. , 2013, Magnetic resonance imaging.
[24] Richard L Ehman,et al. MR elastography derived shear stiffness—a new imaging biomarker for the assessment of early tumor response to chemotherapy , 2014, Magnetic resonance in medicine.
[25] Simon Walker-Samuel,et al. Improving apparent diffusion coefficient estimates and elucidating tumor heterogeneity using Bayesian adaptive smoothing , 2011, Magnetic resonance in medicine.
[26] Mark J. Ratain,et al. Measuring response in a post-RECIST world: from black and white to shades of grey , 2006, Nature Reviews Cancer.
[27] Cynthia A. Reinhart-King,et al. Tensional homeostasis and the malignant phenotype. , 2005, Cancer cell.
[28] R. Ehman,et al. Magnetic resonance elastography , 1996, Nature Medicine.
[29] Barjor Gimi,et al. Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126 , 2007, Cancer biology & therapy.
[30] Ralph Sinkus,et al. Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development. , 2012, European journal of cancer.
[31] Ralph Sinkus,et al. Diagnostic value of MR elastography in addition to contrast-enhanced MR imaging of the breast—initial clinical results , 2010, European Radiology.
[32] F. Westwood,et al. ZD6126: a novel small molecule vascular targeting agent. , 2002, International journal of radiation oncology, biology, physics.